MLchartDataset catalogue

Soliris

Term · Oncology and biomedicine · MLC-T-ONC-007861

A drug used to prevent red blood cells from being destroyed in patients with a rare red blood cell disorder called paroxysmal nocturnal hemoglobinuria (PNH). It is also used to treat another rare disorder called atypical hemolytic urea syndrome (aHUS), in which blood clots form in small blood vessels. Soliris binds to an immune system protein called C5. This helps keep red blood cells from breaking down and helps keep blood clots from forming. Soliris is a type of monoclonal antibody. Also called eculizumab.

Table 1. Record
IdentifierMLC-T-ONC-007861
FieldOncology and biomedicine
Synonymseculizumab
ReferencesNCI Dictionary of Cancer Terms
Record as JSON
{
  "id": "MLC-T-ONC-007861",
  "term": "Soliris",
  "field": "Oncology and biomedicine",
  "definition": "A drug used to prevent red blood cells from being destroyed in patients with a rare red blood cell disorder called paroxysmal nocturnal hemoglobinuria (PNH). It is also used to treat another rare disorder called atypical hemolytic urea syndrome (aHUS), in which blood clots form in small blood vessels. Soliris binds to an immune system protein called C5. This helps keep red blood cells from breaking down and helps keep blood clots from forming. Soliris is a type of monoclonal antibody. Also called eculizumab.",
  "synonyms": [
    "eculizumab"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/soliris/"
}

Record 15,167 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.